Show simple item record

dc.contributor.authorEspinasse, A
dc.contributor.authorSolovyeva, O
dc.contributor.authorDimairo, M
dc.contributor.authorWeir, C
dc.contributor.authorJaki, T
dc.contributor.authorMander, A
dc.contributor.authorKightley, A
dc.contributor.authorEvans, J
dc.contributor.authorLee, S
dc.contributor.authorBedding, A
dc.contributor.authorHopewell, S
dc.contributor.authorRantell, K
dc.contributor.authorLiu, R
dc.contributor.authorChan, A-W
dc.contributor.authorDe Bono, J
dc.contributor.authorYap, C
dc.coverage.spatialEngland
dc.date.accessioned2023-06-23T12:48:53Z
dc.date.available2023-06-23T12:48:53Z
dc.date.issued2023-03-29
dc.identifierARTN e068173
dc.identifierbmjopen-2022-068173
dc.identifier.citationBMJ Open, 2023, 13 (3), pp. e068173 -en_US
dc.identifier.issn2044-6055
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5853
dc.identifier.eissn2044-6055
dc.identifier.eissn2044-6055
dc.identifier.doi10.1136/bmjopen-2022-068173
dc.description.abstractINTRODUCTION: Early phase dose-finding (EPDF) studies are critical for the development of new treatments, directly influencing whether compounds or interventions can be investigated in further trials to confirm their safety and efficacy. There exists guidance for clinical trial protocols and reporting of completed trials in the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) 2013 and CONsolidated Standards Of Reporting Randomised Trials (CONSORT) 2010 statements. However, neither the original statements nor their extensions adequately cover the specific features of EPDF trials. The DEFINE (DosE-FIndiNg Extensions) study aims to enhance transparency, completeness, reproducibility and interpretation of EPDF trial protocols (SPIRIT-DEFINE) and their reports once completed (CONSORT-DEFINE), across all disease areas, building on the original SPIRIT 2013 and CONSORT 2010 statements. METHODS AND ANALYSIS: A methodological review of published EPDF trials will be conducted to identify features and deficiencies in reporting and inform the initial generation of the candidate items. The early draft checklists will be enriched through a review of published and grey literature, real-world examples analysis, citation and reference searches and consultation with international experts, including regulators and journal editors. Development of CONSORT-DEFINE commenced in March 2021, followed by SPIRIT-DEFINE from January 2022. A modified Delphi process, involving worldwide, multidisciplinary and cross-sector key stakeholders, will be run to refine the checklists. An international consensus meeting in autumn 2022 will finalise the list of items to be included in both guidance extensions. ETHICS AND DISSEMINATION: This project was approved by ICR's Committee for Clinical Research. The Health Research Authority confirmed Research Ethics Approval is not required. The dissemination strategy aims to maximise guideline awareness and uptake, including but not limited to dissemination in stakeholder meetings, conferences, peer-reviewed publications and on the EQUATOR Network and DEFINE study websites. REGISTRATION DETAILS: SPIRIT-DEFINE and CONSORT-DEFINE are registered with the EQUATOR Network.
dc.formatElectronic
dc.format.extente068173 -
dc.languageeng
dc.language.isoengen_US
dc.publisherBMJ PUBLISHING GROUPen_US
dc.relation.ispartofBMJ Open
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.subjectEDUCATION & TRAINING (see Medical Education & Training)
dc.subjectProtocols & guidelines
dc.subjectSTATISTICS & RESEARCH METHODS
dc.subjectHumans
dc.subjectChecklist
dc.subjectReference Standards
dc.subjectReproducibility of Results
dc.subjectResearch Design
dc.subjectReview Literature as Topic
dc.subjectConsensus Development Conferences as Topic
dc.titleSPIRIT and CONSORT extensions for early phase dose-finding clinical trials: the DEFINE (DosE-FIndiNg Extensions) study protocol.en_US
dc.typeJournal Article
dcterms.dateAccepted2023-03-29
dc.date.updated2023-06-23T12:47:02Z
rioxxterms.versionVoRen_US
rioxxterms.versionofrecord10.1136/bmjopen-2022-068173en_US
rioxxterms.licenseref.startdate2023-03-29
rioxxterms.typeJournal Article/Reviewen_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/36990492
pubs.issue3
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.publication-statusPublished online
pubs.publisher-urlhttp://dx.doi.org/10.1136/bmjopen-2022-068173
pubs.volume13
icr.researchteamPrCa Targeted Therapyen_US
icr.researchteamClin Trials & Stats Uniten_US
dc.contributor.icrauthorDe Bono, Johann
dc.contributor.icrauthorYap, Christina
icr.provenanceDeposited by Mr Arek Surman (impersonating Prof Kevin Harrington) on 2023-06-23. Deposit type is initial. No. of files: 1. Files: SPIRIT and CONSORT extensions for early phase dose-finding clinical trials the DEFINE (DosE-FIndiNg Extensions) study protoc.pdf


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/